1256256-24-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2h-benzo[b][1,4]oxazine is used as a potential pharmaceutical compound for its unique structure and reactivity. Its potential applications may include the development of new drugs or drug candidates, particularly in the areas of medicinal chemistry and drug discovery.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2h-benzo[b][1,4]oxazine may be utilized as a precursor or intermediate in the synthesis of agrochemicals, such as pesticides or herbicides. Its unique structure and reactivity could contribute to the development of novel and more effective agrochemical products.
Used in Material Sciences:
4-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2h-benzo[b][1,4]oxazine may also find applications in material sciences, where its unique structure and properties could be leveraged to develop new materials with specific characteristics. This could include the creation of advanced polymers, coatings, or other materials with tailored properties for various applications.

Upstream product

• 188947-79-7 6-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 73183-34-3 bis(pinacol)diborane 
• 105655-01-4 6-bromo-3, 4-dihydro-2H-benzo[β][1, 4]oxazine 
• 77901-22-5 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 

Relevant academic research and scientific papers

PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS

The present application provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; method for manufacturing said compound, and its therapeutic uses. The present application further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Rhodium-catalyzed intermolecular C-H silylation of arenes with high steric regiocontrol

Regioselective C-H functionalization of arenes has widespread applications in synthetic chemistry. The regioselectivity of these reactions is often controlled by directing groups or steric hindrance ortho to a potential reaction site. Here, we report a catalytic intermolecular C-H silylation of unactivated arenes that manifests very high regioselectivity through steric effects of substituents meta to a potential site of reactivity. The silyl moiety can be further functionalized under mild conditions but is also inert toward many common organic transformations, rendering the silylarene products useful building blocks. The remote steric effect that we observe results from the steric properties of both the rhodium catalyst and the silane.